OncoVista Innovative Therapies, Inc. (OTC:OVIT) is one of those names that lingers on quote screens long after the working company behind it has gone quiet. Once a San Antonio-based clinical-stage pharmaceutical developer with ambitions in oncology, OncoVista today trades as a sub-penny shell, priced …
● Despite If anything, attention around Prestige has centered on its acquisition-driven growth strategy and the addedLeveragefrom the senior notes offering.
PDS Biotechnology Corporation (NASDAQ:PDSB) has spent 2026 trying to prove that its lead cancer immunotherapy can reach the market faster, even as its share price has slid toward penny-stock territory. The supplied headline frames a "drift lower" and asks whether the pullback is creating …
● Commercial-stage biopharma stocks can be punished even when sales are climbing, and Phathom Pharmaceuticals has felt that tension in 2026.
● Pliant Therapeutics develops integrin-based medicines.
A Form 4 filed on September 10, 2026, discloses that Alexander Otto, a director and reporting person affiliated with KG CURA Vermogensverwaltung G.m.b.H. & Co., sold a combined 254,924 shares of Curbline Properties Corp. common stock across two trading days.
A Form 4 filed on September 8, 2026 disclosed that David Stork, Chief Administrative Officer of Lithia Motors Inc, sold 320 shares of common stock on September 8, 2026.
Cristian Massacesi, Executive Vice President, Chief Medical Officer, and Head of Development at Bristol Myers Squibb, filed a Form 4 on September 10, 2026, reporting the sale of 6,249 shares of common stock on September 9, 2026.
A Form 4 filed on September 10, 2026 with the U.S. Securities and Exchange Commission reports that Shlomi Ben Haim, Chief Executive Officer and Director of JFrog Ltd (NASDAQ:FROG), sold a total of 45,700 ordinary shares on September 8, 2026 across seven separate price …
Tali Notman, Chief Revenue Officer of JFrog Ltd, filed a Form 4 on September 10, 2026, disclosing the sale of ordinary shares on September 8, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.